Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

WuXi PharmaTech Announces Positive Second Quarter Results

publication date: Jul 15, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech (药明康德) reported upbeat Q2 financial results, saying that demand continues strong for its services, which drove revenues and earnings higher. Because the company feels increasingly optimistic about its financial prospects, it also issued higher guidance for the full year. WuXi saw its growth rate drop to just 7% in 2009, despite large capital expenditures to offer new lines of business, and it took a $50 million writedown of its AppTech acquisition in 2008. Now, it expects solid increases in the future. More details...

Stock Symbol: (NYSE: WX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...